Search - tctmd.com

Displaying 1 - 20 of 56

Sort: Relevancy | Date

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Daily News

Even Low Levels of ApoB and LDL Linked With CAD, Mortality: UK Biobank

Michael O'Riordan

January 23, 2024

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Daily News

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Michael O'Riordan

June 14, 2023

News Daily News

Lipid Panels in Standard Precath Blood Draws? Researchers Say It’s Time

Todd Neale

June 13, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Daily News

Too Few Veterans Get Intensified Lipid-Lowering Therapy After Coronary Events

Yael L. Maxwell

October 24, 2022

News Daily News

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

Michael O'Riordan

August 11, 2022

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

News Daily News

Absence of CAC May be Protective Even in Patients With Very High Cholesterol

Michael O'Riordan

February 14, 2022

Advertisement

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Even Low Levels of ApoB and LDL Linked With CAD, Mortality: UK Biobank

Top Coronary Artery Disease News of 2023

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Mortality Risk Varies Among Patients With Very High LDL Levels

LDL Control Remains Poor in CAD Patients: NHANES

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Lipid Panels in Standard Precath Blood Draws? Researchers Say It’s Time

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Too Few Veterans Get Intensified Lipid-Lowering Therapy After Coronary Events

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

Good News and Bad for High-Intensity Statin Use in ASCVD

Absence of CAC May be Protective Even in Patients With Very High Cholesterol

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content